Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Background and study aims Reducing high blood levels of LDL cholesterol decreases the chances of getting a heart attack and other cardiovascular events both in people who have had previous heart attacks (secondary prevention) and in people who have risk factors but have not yet had a heart attack (primary prevention). Statins are drugs that treat high blood cholesterol levels. Many studies show that statins are effective in the primary and secondary prevention of heart attacks and other cardiovascular events. People need to take their statins as prescribed and not to miss doses for the drugs to work properly. Taking drugs as prescribed and not missing doses is called adherence. Many people find it hard to be adherent with their medications all the time. The aim of this study was to investigate if a nurse counselling people about their personal cardiovascular risk factors, including their actual cholesterol levels in the blood, and their personal risk of getting a cardiovascular event would improve adherence to statins without making people anxious. Who can participate? People aged 18 or older who are prescribed statins for prevention of cardiovascular disease. What does the study involve? Participants are randomly allocated to receive either medical care as usual or to receive additional counselling from a nurse about their personal cardiovascular risk factors. What are the possible benefits and risks of participating? The possible benefit of the additional counselling is that it may improve the participants’ adherence with statin treatment and thereby lower (improve) the participants’ blood cholesterol levels. The possible risk of receiving the additional counselling is that receiving information about personal cardiovascular risk factors could make someone anxious about his or her risk of getting a cardiovascular event. Where is the study run from? Academic Medical Center and Slotervaart Hospital, Netherlands. When is the study starting and how long is it expected to run for? The study started in May 2002 and ended in May 2004. Who is funding the study? Pfizer, Netherlands. Who is the main contact? Prof. Erik Stroes [email protected]
Critère d'inclusion
- cardiovascular disease